KR100533576B1 - 세포증식 및 세포사멸 조절용 조성물 및 방법 - Google Patents

세포증식 및 세포사멸 조절용 조성물 및 방법 Download PDF

Info

Publication number
KR100533576B1
KR100533576B1 KR10-2000-7001237A KR20007001237A KR100533576B1 KR 100533576 B1 KR100533576 B1 KR 100533576B1 KR 20007001237 A KR20007001237 A KR 20007001237A KR 100533576 B1 KR100533576 B1 KR 100533576B1
Authority
KR
South Korea
Prior art keywords
dna
mcc
delete delete
phlei
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-2000-7001237A
Other languages
English (en)
Korean (ko)
Other versions
KR20010022643A (ko
Inventor
필립스나이젤씨.
필리온마리오씨.
Original Assignee
바이오니취 라이프 사이언시즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오니취 라이프 사이언시즈 인코포레이티드 filed Critical 바이오니취 라이프 사이언시즈 인코포레이티드
Publication of KR20010022643A publication Critical patent/KR20010022643A/ko
Application granted granted Critical
Publication of KR100533576B1 publication Critical patent/KR100533576B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR10-2000-7001237A 1997-08-05 1998-08-05 세포증식 및 세포사멸 조절용 조성물 및 방법 Expired - Fee Related KR100533576B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US5477797P 1997-08-05 1997-08-05
US60/054,777 1997-08-05
US7506798P 1998-02-18 1998-02-18
US7511198P 1998-02-18 1998-02-18
US60/075,111 1998-02-18
US60/075,067 1998-02-18
US8631798P 1998-05-21 1998-05-21
US60/086,317 1998-05-21
PCT/CA1998/000744 WO1999007383A1 (en) 1997-08-05 1998-08-05 Composition and method for regulating cell proliferation and cell death

Publications (2)

Publication Number Publication Date
KR20010022643A KR20010022643A (ko) 2001-03-26
KR100533576B1 true KR100533576B1 (ko) 2005-12-05

Family

ID=27489673

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2000-7001237A Expired - Fee Related KR100533576B1 (ko) 1997-08-05 1998-08-05 세포증식 및 세포사멸 조절용 조성물 및 방법

Country Status (17)

Country Link
US (2) US6329347B1 (enExample)
EP (1) EP1003525B1 (enExample)
JP (2) JP4335435B2 (enExample)
KR (1) KR100533576B1 (enExample)
AT (1) ATE227996T1 (enExample)
AU (1) AU736450B2 (enExample)
BR (1) BR9815602A (enExample)
CA (1) CA2299548C (enExample)
DE (1) DE69809561T2 (enExample)
DK (1) DK1003525T3 (enExample)
ES (1) ES2187047T3 (enExample)
HU (1) HU227921B1 (enExample)
IL (3) IL134371A0 (enExample)
NO (1) NO322450B1 (enExample)
NZ (1) NZ502674A (enExample)
PT (1) PT1003525E (enExample)
WO (1) WO1999007383A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2299548C (en) 1997-08-05 2009-12-29 Bioniche Inc. Composition and method for regulating cell proliferation and cell death
ES2238780T3 (es) * 1998-02-18 2005-09-01 Bioniche Life Sciences Inc. Tratamiento de cancer de vejiga mediante pared celular de mycobacterium phlei.
DE69920506T2 (de) * 1998-12-04 2005-10-13 Bioniche Life Sciences Inc., London Chemotherapeutische zusammensetzung und verfahren
US6809081B1 (en) * 1998-12-04 2004-10-26 Bioniche Life Sciences, Inc. Chemotherapeutic composition and method
EP1135164B1 (en) * 1998-12-04 2004-08-11 Bioniche Life Sciences Inc. Composition for the treatment of inflammation
ES2238996T3 (es) * 1999-04-01 2005-09-16 Bioniche Life Sciences Inc. Composicion y metodo para inducir apoptosis en celulas de cancer de prostata.
US6794368B1 (en) * 1999-04-01 2004-09-21 Bioniche Life Sciences Inc. Composition and method for inducing apoptosis in prostate cancer cells
WO2000061597A1 (en) 1999-04-08 2000-10-19 Uab Research Foundation Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
WO2001022979A1 (en) * 1999-09-29 2001-04-05 Bioniche Life Sciences Inc. Method to disrupt mitochondrial function
CZ20022372A3 (cs) * 1999-12-13 2002-11-13 Bioniche Life Sciences Inc. Terapeuticky pouľitelné syntetické oligonukleotidy
CA2395493C (en) 1999-12-28 2010-06-22 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
US20030044352A1 (en) * 2001-04-24 2003-03-06 Phillips Nigel C. Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls
US6673566B1 (en) 2002-01-10 2004-01-06 The United States Of America As Represented By The Secretary Of Agriculture Diagnosis of pathogen infections through analysis of nitrite production by antigen stimulated leukocytes
KR101400105B1 (ko) * 2006-07-25 2014-06-19 리폭센 테크놀로지즈 리미티드 Ｎ-말단 폴리시알화
AR083443A1 (es) 2010-10-13 2013-02-27 Bioniche Life Sciences Inc Una composicion que comprende arn bacteriano y paredes celulares bacterianas, metodo para elaborar dicha composicion y sus usos

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172815A (en) 1962-04-24 1965-03-09 Warner Lambert Pharmaceutical Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
FR2160326B1 (enExample) 1971-11-19 1975-02-07 Anvar
US4152423A (en) 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
CA1020460A (en) 1973-02-23 1977-11-08 Wellcome Foundation Limited (The) Isolation of immunostimulating glycopeptide from bacteria
US3976544A (en) 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr) 1976-06-04 1978-07-13 Merieux Inst Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en) 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
DE3011461C2 (de) 1980-03-25 1986-10-30 Dr. Madaus & Co, 5000 Köln Verwendung von Propionibakterien
US4520019A (en) 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579941A (en) 1982-08-13 1986-04-01 Mitsuitoatsu Chemicals, Inc. Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en) 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
BR9406496A (pt) 1993-01-29 1996-01-02 Vetrepharm Inc Processo e composição para estimulação do sistema imunológico em um ser humano ou animal
CA2299548C (en) 1997-08-05 2009-12-29 Bioniche Inc. Composition and method for regulating cell proliferation and cell death

Also Published As

Publication number Publication date
NZ502674A (en) 2002-06-28
WO1999007383B1 (en) 1999-03-25
AU8723698A (en) 1999-03-01
NO20000576L (no) 2000-04-04
IL134371A (en) 2007-07-24
JP2001513504A (ja) 2001-09-04
IL134371A0 (en) 2001-04-30
DK1003525T3 (da) 2003-03-24
ATE227996T1 (de) 2002-12-15
IL180924A (en) 2010-11-30
CA2299548A1 (en) 1999-02-18
US6329347B1 (en) 2001-12-11
HUP0003012A2 (hu) 2000-12-28
JP2008208140A (ja) 2008-09-11
CA2299548C (en) 2009-12-29
NO20000576D0 (no) 2000-02-04
AU736450B2 (en) 2001-07-26
WO1999007383A1 (en) 1999-02-18
JP4335435B2 (ja) 2009-09-30
EP1003525A1 (en) 2000-05-31
NO322450B1 (no) 2006-10-09
HU227921B1 (hu) 2012-06-28
ES2187047T3 (es) 2003-05-16
BR9815602A (pt) 2001-12-11
HUP0003012A3 (en) 2004-03-29
DE69809561D1 (de) 2003-01-02
PT1003525E (pt) 2003-03-31
EP1003525B1 (en) 2002-11-20
DE69809561T2 (de) 2003-09-25
IL180924A0 (en) 2007-07-04
US6326357B1 (en) 2001-12-04
KR20010022643A (ko) 2001-03-26

Similar Documents

Publication Publication Date Title
JP2008208140A (ja) 細胞増殖および細胞死を調節する組成物および方法
CN103354833A (zh) 细菌核糖核酸细胞壁组合物及其制备和使用方法
US7662792B2 (en) Modulation of Fas and FasL expression
AU751667B2 (en) Composition and method for the treatment of bladder cancer
FR2790960A1 (fr) Utilisation de fractions membranaires bacteriennes a activite immunostimulante dans le traitement de cancers, leurs procedes de preparation et les compositions pharmaceutiques les contenant
JP4380922B2 (ja) 化学療法の組成物及び方法
MXPA00001272A (en) Composition and method for regulating cell proliferation and cell death
AU780909B2 (en) Composition and method for inducing apoptosis in prostate cancer cells
US20040242524A1 (en) Chemotherapeutic composition and method
HK1030887B (en) Treatment of bladder cancer by mycobacterium phlei cell wall
MXPA00008142A (en) Composition and method for the treatment of bladder cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20121031

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20131101

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20141128

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20151130

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20151130